drugset / Trial / NCT07561801

Pentoxifylline for Prevention of Contrast Induced Nephropathy in Chronic Kidney Diseased Patients in Intensive Care Unit

NCT07561801

Completed 70 enrolled Tanta University
RandomizedParallel-groupDouble-blindPrevention

Summary

The aim of this study is to evaluate the effect of pentoxifylline for control of contrast induced nephropathy in chronic kidney diseased patients in intensive care unit.

Timeline

Start
2024-07-01
Primary completion
2025-06-01
Completion
2025-06-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Pentoxifylline Small molecule 400 mg Oral